Clinicopathological features, treatment modalities, and prognosis of esophageal neuroendocrine carcinoma: A single‐center retrospective study

Objectives Esophageal neuroendocrine carcinoma (ENEC) is a rare cancer that is highly malignant and related to a poor prognosis. In this retrospective study we aimed to elucidate the clinical characteristics, diagnosis and management of patients with ENEC and to evaluate the potential prognostic factors. Methods Altogether 82 patients diagnosed with ENEC between January 2009 and December 2020 at the Fudan University Shanghai Cancer Center were retrospectively enrolled. Patients’ survival was analyzed using the Kaplan–Meier and log‐rank methods. Univariate and multivariate analyses and a Cox regression model were used to identify the prognostic factors. Results The median overall survival (mOS) was 13 months in all patients. Multivariate analysis revealed that advanced tumor stage (hazard ratio [HR] 2.67, 95% confidence interval [CI] 1.07–6.66, P = 0.0353), liver (HR 3.36, 95% CI 1.53–7.41, P = 0.0026) and lung metastasis (HR 3.37, 95% CI 1.20–9.51, P = 0.0214) were associated with a poor prognosis. While positive chromogranin A (CgA) expression was related to a favorable outcome (HR 0.21, 95% CI 0.09–0.49, P < 0.001). Also, patients had adjustment of chemotherapy (dose reduction or less than three cycles) were prone to a worse prognosis compared with those did not (HR 4.36, 95% CI 2.10–9.08, P < 0.001). Conclusion In patients with ENEC, advanced cancer stage, adjustment of chemotherapy, liver and lung metastasis were associated with a poor survival, while CgA expression was related to a favorable prognosis.